Synthesis and structure-activity relationships of ring-opened 17-hydroxywortmannins: Potent phosphoinositide 3-kinase inhibitors with improved properties and anticancer efficacy

Journal of Medicinal Chemistry

Volumn 51, Issue 5, 2008, Pages 1319-1323

  Zask, Arie ^a   Kaplan, Joshua ^a   Toral Barza, Lourdes ^a   Hollander, Irwin ^a   Young, Mairead ^a   Tischler, Mark ^a   Gaydos, Christine ^a   Cinque, Michael ^a   Lucas, Judy ^a   Yu, Ker ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[[3 (DIMETHYLAMINO)PROPYL](METHYL)AMINO]METHYLENE] 7,11 DIHYDROXY 4 (METHOXYMETHYL) 4A,6A DIMETHYL 2,10 DIOXO 1,2,4,4A,5,6,6A,7,8,9,9A,10 DODECAHYDROINDENO[4,5 H]ISOCHROMEN 5 YL ACETATE; 17 HYDROXYWORTMANNIN; 2 MORPHOLINO 8 PHENYLCHROMONE; AMINE; ENZYME INHIBITOR; FURAN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE 3 KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SOLUBILITY; DRUG STABILITY; ENZYME INHIBITION; GLIOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; RING OPENING; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; ANIMALS; ANTINEOPLASTIC AGENTS; BENZOPYRANS; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; INDENES; MICE; MICE, NUDE; SOLUBILITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 41649109390     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm7012858     Document Type: Article

References (18)

1. Engelman, J. A.; Luo, J.; Cantley, L. C. The Evolution of Phosphatidylinositol 3-Kinases as Regulators of Growth and Metabolism. Nat. Rev. Genet. 2006, 7, 606-619.
2. Verheijen, J.; Zask, A. Phosphatidylinositol 3-Kinase (PI3K) Inhibitors as Anticancer Drugs. Drugs Future 2007, 32, 537-547.
3. Walker, E. H.; Pacold, M. E.; Perisic, O.; Stephens, L.; Hawkins, P. T.; Wymann, M. P.; Williams, R. L. Structural Determinants of Phosphoinositide 3-Kinase Inhibition by Wortmannin, LY294002, Quercetin, Myricetin, and Staurosporine. Mol. Cell 2000, 6, 909-919.
4. Schultz, R. M.; Merriman, R. L.; Andis, S. L.; Bonjouklian, R.; Grindey, G. B.; Rutherford, P. G.; Gallegos, A.; Massey, K.; Powis, G. In Vitro and in Vivo Antitumor Activity of the Phosphatidylinositol-3-kinase Inhibitor, Wortmannin. Anticancer Res. 1995, 15, 1135-1139.
5. Norman, B. H.; Shih, C.; Toth, J. E.; Ray, J. E.; Dodge, J. A.; Johnson, D. W.; Rutherford, P. G.; Schultz, R. M.; Worzalla, J. F.; Vlahos, C. J. Studies on the Mechanism of Phosphatidylinositol 3-Kinase Inhibition by Wortmannin and Related Analogs. J. Med. Chem. 1996, 39, 1106-1111.
6. Yu, K.; Lucas, J.; Zhu, T.; Zask, A.; Gaydos, C.; Toral-Barza, L.; Gu, J.; Li, F.; Chaudhary, I.; Cai, P.; Lotvin, J.; Petersen, R.; Ruppen, M.; Fawzi, M.; Ayral-Kaloustian, S.; Skotnicki, J.; Mansour, T.; Frost, P.; Gibbons, J. PWT-458, a Novel Pegylated-17-Hydroxywortmannin, Inhibits Phosphatidylinositol 3-Kinase Signaling and Suppresses Growth of Solid Tumors. Cancer Biol. Ther. 2005, 5, 538-545.
7. Zhu, T.; Gu, J.; Yu, K.; Lucas, J.; Cai, P.; Tsao, R.; Gong, Y.; Li, F.; Chaudhary, I.; Desai, P.; Ruppen, R.; Fawzi, M.; Gibbons, G.; Ayral-Kaloustian, S.; Skotnicki, J.; Mansour, T.; Zask, A. Pegylated Wortmannin and 17-Hydroxywortmannin Conjugates as Phosphoinositide 3-Kinase Inhibitors Active in Human Tumor Xenograft Models. J. Med. Chem. 2006, 49, 1373-1378.
8. Haefliger, W.; Kis, Z.; Hauser, D. Selective Functionalization of Wortmannin with the Help of a Masked Furan Ring. Helv. Chim. Acta 1975, 58, 1620-1628.
9. Norman, B. H.; Shih, C.; Toth, J. E.; Ray, J. E.; Dodge, J. A.; Johnson, D. W.; Rutherford, P. G.; Schultz, R. M.; Worzalla, J. F.; Vlahos, C. J. Studies on the Mechanism of Phosphatidylinositol 3-Kinase Inhibition by Wortmannin and Related Analogs. J. Med. Chem. 1996, 39, 1106-1111.
10. Wipf, P.; Minion, D. J.; Halter, R. J.; Berggren, M. I.; Ho, C. B.; Chiang, G. G.; Kirkpatrick, L.; Abraham, R.; Powis, G. Synthesis and Biological Evaluation of Synthetic Viridins Derived From C(20)-Heteroalkylation of the Steroidal PI-3-Kinase Inhibitor Wortmannin. Org. Biomol. Chem. 2004, 2, 1911-1920.
11. Ihle, N. T.; Williams, R.; Chow, S.; Chew, W.; Berggren, M. I.; Paine-Murrieta, G.; Minion, D. J.; Halter, R. J.; Wipf, P.; Abraham, R.; Kirkpatrick, L.; Powis, G. Molecular Pharmacology and Antitumor Activity of PX-866, a Novel Inhibitor of Phosphoinositide-3-Kinase Signaling. Mol. Cancer Ther. 2004, 3, 763-772.
12. Isosaki, M. Inhibition of Wortmannin Activities by Amino Compounds. Biochem. Biophys. Res. Commun. 2004, 324, 1406-1412.
13. Yuan, H.; Luo, J.; Weissleder, R.; Cantley, L.; Josephson, L. Wortmannin-C20 Conjugates Generate Wortmannin. J. Med. Chem. 2006, 49, 740-747.
14. Holleran, J. L.; Egorin, M. J.; Zuhowski, E. G.; Parise, R. A.; Musser, S. M.; Pan, S. Use of High-Performance Liquid Chromatography to Characterize the Rapid Decomposition of Wortmannin in Tissue Culture Media. Anal. Biochem. 2003, 323, 19-25.
15. Yuan, H.; Barnes, K. R.; Weissleder, R.; Cantley, L.; Josephson, L. Covalent Reactions of Wortmannin under Physiological Conditions. Chem. Biol. 2007, 14, 321-328.
16. Yu, K.; Toral-Barza, L.; Shi, C.; Zhang, W.-G.; Zask, A. Response and Determinants of Cancer Cell Susceptibility to PI3K Inhibitors: Combined Targeting of PI3K and Mek1 as an Effective Anticancer Strategy. Cancer Biol. Ther., in press.
17. Toral-Barza, L.; Zhang, W. G.; Lamison, C.; Larocque, J.; Gibbons, J.; Yu, K. Characterization of the Cloned Full-Length and a Truncated Human Target of Rapamycin: Activity, Specificity, and Enzyme Inhibition as Studied by a High Capacity Assay. Biochem. Biophys. Res. Commun. 2005, 332, 304-310.
18. Yu, K.; Toral-Barza, L.; Discafani, C.; Zhang, W. G.; Skotnicki, J.; Frost, P.; Gibbons, J. mTOR, a Novel Target in Breast Cancer: The Effect of CCI-779, an mTOR Inhibitor, in Preclinical Models of Breast Cancer. Endocr.-Relat. Cancer 2001, 8, 249-258.